Overview

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Status:
Active, not recruiting

Trial end date:
2023-12-12

Target enrollment:

Participant gender:

Summary

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets. CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens. The investigational CAR T cells and proposed indications are as follows: CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.

Phase:

N/A

Details

Lead Sponsor:

Kang YU

Collaborators:

CARsgen Therapeutics Co., Ltd.
Carsgen Therapeutics, Ltd.

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate